Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909779 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 841
- Enrollment target
NCT00909779 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 841 participants.
The verdict
NCT00909779, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 841 participants
- Enrollment target
Study Summary
This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.
Interventions
- DRUG Placebo
- DRUG Arformoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 841 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909779
The ClinicalTrials.gov registry entry for NCT00909779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 841 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00909779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909779 about?
NCT00909779 is a clinical study titled "Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects". This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.
What is the current status of trial NCT00909779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 841 participants. The study started on 2009-06. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00909779?
The interventions under investigation include: Placebo (DRUG), Arformoterol (DRUG).
Who is sponsoring clinical trial NCT00909779?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.